Mukonex (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mukonex, is a mucolytic presented as an oral formulation for oral use. It treats acute and chronic bronchitis, cough with thick mucus, chronic obstructive pulmonary disease (COPD) and asthma with productive cough in adults.

GNH USA supplies Mukonex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ambroxol Hydrochloride is used to manage respiratory conditions characterized by thick or viscous mucus.

Acute bronchitis: helps clear mucus and reduces cough frequency. Chronic bronchitis: improves mucus clearance and eases expectoration. Chronic obstructive pulmonary disease (COPD): reduces sputum viscosity and facilitates airway drainage. Asthma with productive cough: aids removal of bronchial secretions and eases breathing.

Adverse reactions may occur with any mucolytic therapy. Most are mild and reversible.

Common Side Effects: - Nausea - Diarrhea - Altered taste sensation - Skin rash or pruritus - Headache - Dizziness

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatotoxicity manifested by elevated liver enzymes - Hematologic abnormalities such as leukopenia or thrombocytopenia

Use Ambroxol Hydrochloride with appropriate clinical oversight and consider patient‑specific factors.

Assess renal function before initiating therapy: dose adjustment may be needed in severe impairment. Monitor hepatic status: avoid or use cautiously in patients with liver disease. Watch for hypersensitivity: discontinue if rash, swelling or breathing difficulty develop. Avoid in known Ambroxol allergy: contraindicated in individuals with documented hypersensitivity. Pregnancy and lactation: safety not established, prescribe only if benefit outweighs risk. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ambroxol Hydrochloride may influence the safety or efficacy of other medicines.

Major Interactions (Avoid): - Concomitant use with other mucolytics may increase gastrointestinal irritation. - Combination with drugs that prolong the QT interval may heighten arrhythmia risk. - Co‑administration with strong anticholinergic agents may reduce mucociliary clearance benefits.

Moderate Interactions (Monitor Closely): - Oral anticoagulants: monitor INR or clotting parameters. - NSAIDs: may increase risk of gastrointestinal upset. - Antihistamines or sedatives: possible additive central nervous system effects. - Antibiotics metabolized by hepatic enzymes: monitor for altered plasma levels.